The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. [electronic resource]
Producer: 20200508Description: 69-77 p. digitalISSN:- 1879-0852
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Bone Neoplasms -- drug therapy
- Carcinoma, Renal Cell -- drug therapy
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug-Related Side Effects and Adverse Reactions -- prevention & control
- Duration of Therapy
- Feasibility Studies
- Female
- Humans
- Kidney Neoplasms -- pathology
- Liver Neoplasms -- drug therapy
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Patient Reported Outcome Measures
- Progression-Free Survival
- Sunitinib -- administration & dosage
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.